Aehr Test Systems, Inc.

Background

Company Name	Aehr Test Systems, Inc.
Stock Symbol	AEHR
Class Period	January 09, 2024 to March 24, 2024
Lead Plaintiff Motion Deadline	February 03, 2025

Submit Your Information

If you suffered a loss on your Aehr Test Systems, Inc. investments or would like to inquire about joining an action to recover your loss under the federal securities laws, please complete the form below. Please note that submission of this form does not by itself form an attorney-client relationship nor does filing out this form mean you have joined any lawsuit.

First Name*

Middle Initial

Last Name*

Email*

Phone*

If representing a Corporation, Trust, Partnership or other entity, Name of Entity

If representing an Entity, Position at Entity

Mailing Address

City

State/Province

ZIP/Postal Code

Country

Are you a current or former employee of the company?

Did you purchase any shares before January 09, 2024?

Shares Purchased

Number of Shares	Buy Date	Price Per Share	Add
Purchased quantity	Purchased month Purchased day Purchased year

Shares Sold

Number of Shares	Sell Date	Price Per Share	Add
	Sold month Sold day Sold year

Additional Comments

Background

On March 25, 2024, Aehr released its preliminary third quarter fiscal 2024 financial results, revealing that the Company expected revenue to be approximately $7.6 million, significantly missing consensus estimates of $14.3 million, citing delays in wafer level burn-in system orders for semiconductor devices used in electric vehicles that created a short-term gap in revenue and profitability. Further, the Company lowered its 2024 revenue forecast by approximately $15 million.

On this news, Aehr’s stock price fell $3.29, or 22.4%, to close at $11.37 per share on March 25, 2024, thereby injuring investors.

The complaint filed in this class action alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company’s business, operations, and prospects. Specifically, Defendants failed to disclose to investors that: (1) contrary to prior representations to investors, Aehr was continuing to experience substantial delays in customer orders; (2) the foregoing issue was likely to have a material negative impact on the Company’s revenue growth; (3) accordingly, the Company’s business and/or financial prospects were overstated; and (4) as a result, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis at all relevant times.

Submit Your Information